S

Sanofi

Global pharma company; vaccines and R&D

Global Lead Buyer - Digital Delivery & Operations

Full-TimePosted on 10/20/2026Deadline 11/15/26
€59.6k - €79.5k
Senior
Master's
Barcelona, Spain
Hybrid
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • At least five years of experience in procurement or a related field, such as buying, sales, partnerships, outsourcing, or project management.
  • A minimum Master degree from an accredited college or university.
  • Fluency in English.
  • Professional sourcing skills and the ability to develop relationships across lines of business and the Procurement organization, including transversal and project management skills in a multicultural environment.
  • Technical knowledge of the relevant subcategories and domain, and mastery of negotiation techniques.
  • A good understanding of business, operations, and legal aspects, including service level agreements and key performance indicators.
  • Strong analytical and problem-solving skills; flexibility, receptiveness, resourcefulness, and creativity.
  • Assertiveness, communication, organizational, and presentation skills, interpersonal sensitivity, and the ability to interact confidently with stakeholders and vendors.
  • Influential management skills, including the ability to convince and persuade others regarding appropriate solutions.
  • Experience and confidence managing complex and undefined business situations.
  • Ability to work in a complex, multifunctional matrix organization across functions, countries, and cultures.
  • A strategic and innovative approach to business solutions while complying with external and internal policies.
  • Transversal management skills and a strong commitment to ethics, business integrity, and compliance.
Responsibilities
  • Build and execute a competitive, innovative sourcing initiative pipeline based on spend and existing landscape analysis, market intelligence, business needs, risks, and opportunities; align initiatives with budgets and long-range plans and deliver business value.
  • Participate in defining and implementing category strategies in accordance with category managers’ recommendations.
  • Anticipate and consolidate business needs globally to optimize global negotiations.
  • Lead strategic sourcing initiatives and negotiations, focusing on business operational impact improvement and aligning with category strategies.
  • Develop and share expertise about supplier markets within and outside the Procurement Domain and with stakeholders, including knowledge of new suppliers, technologies, and substitute products.
  • Achieve the goals set by the reporting Business Partner and deliver a savings pipeline in line with targets.
  • Coach Global Buyers in sourcing strategies, negotiation tactics, and market knowledge.
  • Communicate proactively about ongoing sourcing activities within and outside the Procurement Domain, and engage proactively with other Procurement Domains.
  • Deliver robust supplier management through business reviews and performance management.
  • Ensure mastery of procurement technical excellence, including total cost of ownership, supplier relationship management, market intelligence, risk management, innovation, corporate social responsibility, health, safety and environment, compliance, and quality.
  • Work closely with procurement services to leverage middle- and back-office services.
  • Engage key Digital stakeholders and selected stakeholders in other global business units upfront, and develop strong partnerships and supportive two-way relationships with key stakeholders.
  • Present Procurement strategies to key internal customers for review and input.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...